Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial
| By Sequoia Administrator | 0 Comments
Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial
Continue reading...
Recent Posts
- Sarepta Duchenne gene therapy wins broader use from FDA
- The Dangers, Cost of Weight Loss Drugs and How to Avoid a “Life Sentence” of Dependency On Them
- Bristol Myers secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma
- BMS CAR-T Therapy Wins FDA Approval for Expanded Use in Follicular Lymphoma
- Pfizer will charge $3.5M for its first FDA- approved gene therapy
Archives
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- June 2023
- May 2023
- April 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- November 2021
- October 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- December 2020
- October 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
Recent Comments